Table 12 Summary of findings about the role of liquid biopsy in stool samples
Type of marker | Type of tumor | Study endpoint | Findings | Reference |
|---|---|---|---|---|
DNA | CRC | Early diagnosis | Fecal DNA mutation panel showed a high sensitivity for early cancer detection compared to fecal immunochemistry and occult blood testing | |
DNA | Pancreatic cancer | Analysis of KRAS mutation status | High concordance of KRAS mutation status between stool and tissue | Caldas 1994 [368] |
DNA | Gastric cancer | Early diagnosis | The analysis of fecal DNA mutations provide diagnostic information | Youssef 2017 [369] |
DNA | Melanoma, NSCL | Analysis of microbiome as predictor of immunotherapy response and toxicity | Specific microbiome compositions are predictive of immunotherapy response and toxicity | Allen-Vercoe 2020; Xu 2020; Davar 2021; Baruch 2021; Sivan 2015; Vétizou 2015 [251, 370,371,372,373,374] |
miRNA | CRC | Early diagnosis | The expression of specific miRNAs showed a high sensitivity in early cancer detection | Wu 2012; Raut 2021; Liu 2016; Bastaminejad 2017; Phua 2014; Duran-Sanchon 2020; Duran-Sanchon 2021 [375,376,377,378,379,380,381] |
lncRNA | CRC | Early diagnosis | cancer-related lncRNA panels to identify and distinguish CRC patients from healthy individuals | Gharib 2021 [382] |